Expertise in
13
conditions

Carlo B. Passerini-Gambacorti

Monza, IT 
Expertise in
13
conditions
Monza, IT 

Overview

Carlo Passerini-Gambacorti practices practicing medicine in Monza, Italy.

Mr. Passerini-Gambacorti is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Anaplastic Large Cell Lymphoma, T-Cell Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 193 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Monza, Italy
Other Locations
Milan, Italy
San Gerardo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)
A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)
Enrollment Status: Completed
Publish Date: June 10, 2026
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
Retro-prospective Observational Study on Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR - PRO)
Retro-prospective Observational Study on Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR - PRO)
Enrollment Status: Completed
Publish Date: July 29, 2025
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Enrollment Status: Completed
Publish Date: March 06, 2023
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy
Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy
Enrollment Status: Completed
Publish Date: November 05, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 5 Less Clinical Trials

193 Total Publications

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.
DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.
Journal: EJHaem
Published: July 14, 2026

Frequently Asked Questions about Carlo B. Passerini-Gambacorti

Is Carlo B. Passerini-Gambacorti a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Carlo B. Passerini-Gambacorti is classified as an Elite expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carlo B. Passerini-Gambacorti participate in research or clinical trials?

Yes. Carlo B. Passerini-Gambacorti has published 193 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Carlo B. Passerini-Gambacorti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Passerini-Gambacorti's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile